Oppenheimer analyst Suraj Kalia initiated coverage of Pulse Biosciences (PLSE) with an Outperform rating and $22 price target The company has developed nanosecond pulsed field ablation technology and preliminary evidence suggests a better safety and efficacy profile versus traditional treatments in key applications like thyroid ablation, the analyst tells investors in a research note. The firm says Pulse has multiple shots on goal and an experienced CEO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLSE: